^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FOXA1 (Forkhead Box A1)

    i
    Other names: FOXA1, Forkhead Box A1, Hepatocyte Nuclear Factor 3-Alpha, Forkhead Box Protein A1, Transcription Factor 3A, HNF-3-Alpha, HNF-3A, TCF-3A, HNF3A, TCF3A, Hepatocyte Nuclear Factor 3 Alpha
    10d
    FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy. (PubMed, Int J Mol Sci)
    The effects of FOXA1 inhibition on sensitivity to carboplatin and the immune checkpoint inhibitor atezolizumab were also examined. Its overexpression correlates with disease progression, supporting its potential as a biomarker and therapeutic target. Targeting FOXA1 could enhance immunotherapy efficacy and help overcome chemoresistance in ovarian cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FOXA1 (Forkhead Box A1)
    |
    Tecentriq (atezolizumab) • carboplatin
    14d
    Appropriate normalization is critical to improve reproducibility of tissue ChIP-seq. (PubMed, Serican J Med)
    Lastly, input-adjusted spike-in normalization further accounts for differences in input chromatin amount across samples, which is especially crucial for tissue ChIP-seq that often starts with different amounts of input chromatin. Overall, our study demonstrated that appropriate normalization is essential to improve the reproducibility and comparability of ChIP-seq experiments and highlighted the importance of input-adjusted spike-in normalization for tissue ChIP-seq.
    Journal
    |
    FOXA1 (Forkhead Box A1)
    21d
    A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer. (PubMed, Front Mol Biosci)
    Functional characterization showed that RNF11 regulates proliferation and migration of bladder cancer. These findings highlight the prognostic value of CAF signatures and provide a framework for precision medicine approaches in bladder cancer management.
    Journal
    |
    FOXA1 (Forkhead Box A1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    22d
    FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity. (PubMed, Cell Rep)
    Integrated RNA-seq, ATAC-seq, and ChIP-seq reveal that L1-like specification involves a hybrid androgen receptor/FOXA1 motif and cooperation with POU2F1. In vivo, these same alleles, combined with Trp53/Pten loss, shift tumor histology from basal-like to secretory luminal phenotypes.
    Licensing / partnership • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • FOXA1 (Forkhead Box A1)
    27d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    2ms
    Extracellular matrix regulates lineage plasticity in prostate cancer through YAP/TEAD. (PubMed, bioRxiv)
    We find that lineage transition is accompanied by a redistribution of FOXA1 and TEAD cistromes from PRAD to NEPC-specific enhancers and requires the pioneering activity of FOXA1. Thus, extracellular matrix/integrin signaling in the PRAD tumor microenvironment restrains NE lineage plasticity, highlighting a potential path for pharmacological inhibitors in modulating treatment-induced lineage change.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • YAP1 (Yes associated protein 1) • FOXA1 (Forkhead Box A1) • LATS1 (Large Tumor Suppressor Kinase 1) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • ITGB1 (Integrin Subunit Beta 1) • TAFAZZIN (Tafazzin)
    2ms
    FOXA1 Alterations in Prostate Cancer: Expression, Mutation Classes, and Copy Number Changes. (PubMed, In Vivo)
    FOXA1 defines a major oncogenic axis in prostate cancer, distinct from TMPRSS2-ERG fusion and PROX1 induction. Class 1 and 2 FOXA1 mutations drive alternative transcriptional programs leading to therapy resistance, highlighting FOXA1 as a critical biomarker and target for chromatin-directed interventions.
    Journal
    |
    ERG (ETS Transcription Factor ERG) • FOXA1 (Forkhead Box A1) • TMPRSS2 (Transmembrane serine protease 2)
    |
    TMPRSS2-ERG fusion
    2ms
    Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors. (PubMed, Breast Cancer Res)
    Luminal Androgen Receptor and Molecular Apocrine Breast Cancers constitute a single molecular entity within estrogen receptor-negative breast cancers. The validated four-gene signature enables robust clinical identification and may guide future therapeutic stratification.
    Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor) • FOXA1 (Forkhead Box A1) • TFF3 (Trefoil factor 3) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor)
    |
    ER negative
    2ms
    SPDEF-mediated BIRC5 transcriptional activation enhances non-small cell lung cancer progression. (PubMed, Mutat Res)
    Our findings demonstrate the tumor-promoting function of SPDEF in NSCLC by transcriptionally activating BIRC5, highlighting SPDEF as a candidate target for future NSCLC-directed therapies.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • FOXA1 (Forkhead Box A1) • GATA6 (GATA Binding Protein 6) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor)
    2ms
    CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2-p53 Axis. (PubMed, Research (Wash D C))
    These findings establish the CDK12-FOXA1-MDM2 axis as a pivotal driver of PCa progression and underscore the therapeutic potential of targeting FOXA1 phosphorylation to restore tumor suppressor function and induce apoptosis in PCa. Our work provides a mechanistic framework for developing precision therapies aimed at disrupting this oncogenic cascade in PCa.
    Journal
    |
    TP53 (Tumor protein P53) • CDK12 (Cyclin dependent kinase 12) • FOXA1 (Forkhead Box A1)
    2ms
    Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma. (PubMed, Eur J Med Res)
    CDH13 is highly expressed in HCC and may promote angiogenesis, immune evasion, and metabolic reprogramming via the FOXA1-CDH13 axis, suggesting its potential as a therapeutic target.
    Journal • IO biomarker
    |
    FOXA1 (Forkhead Box A1) • MIF (Macrophage Migration Inhibitory Factor)
    |
    docetaxel
    2ms
    BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction. (PubMed, Nat Commun)
    Importantly, BPTF interacts with AR through its bromodomain, and a BPTF bromodomain inhibitor disrupts this interaction, impairs AR signaling and suppresses PCa cell growth. In summary, our findings establish BPTF as a critical regulator of AR activity by promoting chromatin accessibility and stabilizing the AR-FOXA1 complex, highlighting BPTF as a potential therapeutic target in prostate cancer.
    Journal
    |
    FOXA1 (Forkhead Box A1) • BPTF (Bromodomain PHD Finger Transcription Factor)